- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
SGEN Market Currents
more »
-
May 9 Seattle Genetics (SGEN +2.1%) erases a +5% loss at the open, despite posting a Q1 revenue miss late yesterday. Total revenue actually jumped nearly 300% Y/Y, driven by higher sales of its lymphoma drug Adcetris. RBC Capital says the company still has multiple market expansion opportunities, and should be bought on weakness.
1 Comment
SGEN in Focus
more »
SGEN Related Articles
more »
SGEN News
more »
-
at MarketWatch.com (Feb 14, 2012)
-
at MarketWatch.com (Feb 13, 2012)
-
at MarketWatch.com (Aug 18, 2011)
-
at MarketWatch.com (Jul 15, 2011)
-
at CNBC.com (Jun 22, 2011)
SGEN Press Releases and Filings
more »
-
Business Wire (Wed, 9:00AM)
-
Business Wire (May 16, 2012)
-
Business Wire (May 11, 2012)
-
Business Wire (May 10, 2012)
-
Business Wire (May 8, 2012)
SGEN Latest Transcript
more »
-
Mon, Nov 1, 2010Popular searches: lymphoma, SGEN, trials, aethera, now, accelerated, compugen, first, lintuzumab, product.
SGEN Cramer
more »
-
Fri, Mar 25, 2011
-
Thu, Nov 5, 2009
SGEN Instablog posts
more »
SGEN vs. ETF Alternatives
Company Description
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. We initiated a pivotal trial of our lead product candidate, SGN-35, during the first quarter of... More
